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Disorders of Fatty Acid Oxidation in the
Era of Tandem Mass Spectrometry in
Newborn Screening
Sandra A. Banta-Wright, RNC, MN, NNP, Kathleen C. Shelton, PhD, PNP,
and Michael J. Bennett, PhD, FRCPath, FACB

With recent advances in laboratory technology with tandem mass spectrometry (MS/MS), the number of
infants identified with a fatty acid oxidation disorder has increased dramatically. Disorders of fatty acid
oxidation comprise one of the most rapidly growing groups within the field of errors of metabolism. This
review will explore the recent developments in newborn screening related to the use of tandem mass
spectrometry and disorders of fatty acid oxidation.
Keywords: Fatty acid oxidation; Tandem mass spectrometry

In 1961, Guthrie and Susi1 developed a sensitive but simple and
inexpensive screening test for phenylketonuria (PKU). This
screening test used a bacterial inhibition assay of dried blood
collected on filter paper to measure phenylalanine. With early
identification of newborns with PKU, early initiation of a diet
low in phenylalanine resulted in normal cognitive development
rather than severe mental retardation associated with classic
untreated PKU.2 By 1961, Oregon and Massachusetts began
screening every newborn in those states for PKU.3 By the late
1960s, the practice of routine newborn screening for PKU had
expanded to almost every state and, soon afterward, to most
developed countries. Within three decades, all states and

territories in the United States had instituted universal newborn
screening for PKU. 4-7 Subsequently, newborn screening
programs have added screening tests for other disorders,
including amino acidopathies, galactosemia, congenital
hypothyroidism, and sickle cell disease. The disorders were
added based upon the principles of newborn screening.8-10
Almost all of the disorders screened and identified by newborn
screening programs are mendelian or inherited conditions.
However, other conditions, such as HIV and congenital
toxoplasmosis, have been included in some screening
programs.11,12 For a few of the disorders, the evidence for efficacy
of early medical intervention that early screening allowed was
overwhelming, as with PKU and congenital hypothyroidism.2,13
In other cases, the benefits of medical intervention were less
dramatic but significant enough to warrant screening.14,15
As more disorders were added to the original screening for
PKU, the laboratory needs increased because each disorder had
a separate assay: universal newborn screening continued to rely
on the “one test-one disorder” system. Screening needed to be
more efficient and comprehensive. The development of a single
assay that could be used to detect several disorders from a
single sample was desired. With advances in technology,
tandem mass spectrometry (MS/MS) provided a mechanism to
screen for multiple metabolic disorders using a single
sample.16,17 This technology can detect an array of metabolic
disorders, including amino acids disorders, fatty acid oxidation
disorders (FAODs), and organic acidemias during the neonatal
period many times before a catastrophic event (Table 1).18-25
The purpose of this review is to explore the recent
developments in the field of newborn screening related to
the use of tandem mass spectrometry and disorders of fatty
acid oxidation.

Tandem Mass Spectrometer
History of Tandem Mass Spectrometer
A tandem mass spectrometer (MS/MS) is one type of analytical
instrument used in laboratories. (Fig 1). This instrument can
analyze numerous compounds, such as those in body fluids,
foods, and pharmaceuticals. Simplistically, the single mass

spectrometer (MS) weighs molecules (Fig 2). As molecules are
extremely small and cannot be weighed in the usual method on a
scale, the MS weighs molecules electronically and can determine
each molecule's unique mass and how much of the compound is
present in the material that is being analyzed. A good analogy for
this is pocket change. When you grab a handful of coins, you may
have pennies, dimes, nickels, and quarters. If you sort these from
lightest to heaviest, the dimes would be the lightest, whereas the
quarters would be the heaviest. The other coins would fall

Table 1. Summary of Inborn Errors of Metabolism Detectable Through Tandem Mass Spectrometry
During the Neonatal Period
Amino Acid Disorders
Argininemia

Argininosuccinic acid lyase
deficiency (ASA)
Citrullinemia (CIT)

Fatty Acid Disorders
Carnitine acylcarnitine translocase
deficiency (CACT)

Carnitine palmitoyl transferease
deficiency, type I (CPT I)

Homocystinuria (HCY)
Hypermethioninemia (MET)
Hyperphenylalaninemias:
Classical PKU (PKU),
Benign Hyperphenylalaninemia
(H-PHE), Biopterin Cofactor
Defects (BIOPT)
Maple syrup urine disease (MSUD)

Carnitine palmitoyl transferase
deficiency, type II (CPT II)
Carnitine uptake defect/transport
deficiency (CUD)

2,4-Dienoyl-coenzyme A reductase
deficiency (DE RED)
Long chain acyl-coenzyme A
dehydrogenase deficiency (LCAD)
Long chain 3-hydroxyacyl-coenzyme A
dehydrogenase deficiency (LCHAD)/
Trifunctional protein deficiency (TFP)
Medium chain acyl-coenzyme A
dehydrogenase deficiency (MCAD)
Medium/Short chain
3-hydroxyacyl-coenzyme A dehydrogenase
deficiency (MCHAD/SCHAD)
Medium chain 3-ketoacyl-coenzyme
A thiolase deficiency (MCAT)
Multiple acyl-coenzyme A
dehydrogenase deficiency (MADD or
GAII, Glutaric acidemia, type II)
Short chain acyl-coenzyme A
dehydrogenase deficiency (SCAD)
Very long chain acyl-coenzyme A
dehydrogenase deficiency (VLCAD)

Organic Acid Disorders
2-Methylbutyryl-coenzyme
A dehydrogenase deficiency
(2MBG or 2MBCD or SBCAD)
2-Methyl-3-OH butyric aciduria
(2M3HBA)
3-Hydroxy-3-methylglutaryl
deficiency (HMG)
3-Methylcrotonyl-coenzyme A
carboxylase deficiency (3MCC)
3-Methylgluta-cronyl-coenzyme
A hydratase deficiency (3MGA)
Glutaric acidemia, type I (GA-I)
Isobutyrylglycinuria deficiency (IBG)
Isovaleric acidemia (IVA)

Malonic acidemia (MAL)
Methylmalonic acidemias (MMA)
Mitochondrial acetoacetyl-coenzyme
A thiolase deficiency (SKAT, BKT,
3-ketothiolase deficiency, β ketothiolase)
Multiple carboxylase deficiency (MCD)
Propionic acidemia (PA)

Data from Sweetman L, Millington DS, Therrell BL et al: Naming and counting disorders (conditions) include in newborn screening. Pediatrics 2006;117:S308S314; Millington D, Koeberl D. Metabolic Screening in the newborn. Growth, Genetics & Hormones 2003;19(3):33-38; Zytkovicz TH, Fitzgerald EF, Marsden D,
et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a 2-year summary from the New England
Newborn Screening Program. Clinical Chemistry 2001;47(11):1945-1955; Rinaldo P, Matern D. Disorders of fatty acid transport and mitochondrial oxidation:
Challenges and dilemmas of metabolic evaluation. Genetics in Medicine 2000;2(6):338-34. Rashed MS, Rahbeeni Z, Ozand PT. Application of electrospray tandem
mass spectrometry to neonatal screening. Seminars in Perinatology 1999;23(2), 183-193.

than the groups of dimes, nickels, pennies, and quarters. The
MS/MS analysis produces a report on the type and amount of
each analyte present in the sample.

Tandem Mass Spectrometer and Universal
Screening

Fig 1. Tandem mass spectrometer. Reprinted with
permission from Waters Corporation (MS Technologies
Centre, Milford, MA).
between the dimes and the quarters. The MS sorts molecules by
weight in much the same way.
An MS/MS is simply two single MS with a special “collision
cell” chamber between the two MS instruments (Fig 3).26 After
being prepped, the sample is injected into the first instrument.
While in the first instrument, the sample is ionized to produce
molecular ions, which are determined based upon mass-tocharge (m/z) ratio. The ionized molecules are sorted and
weighed. Next, the sample is sent into the collision cell chamber
where the molecular ion sample is broken into fragmented
pieces, called analytes, which are like pieces of a puzzle. Then
the sample is passed into the second instrument where
quantities of the selected analyte(s) are sorted and weighed
according to their m/z ratio. The peak of each analyte is
compared with internal standard to yield both a qualitative and
quantitative result. The result can be analyzed within minutes to
produce histograms for analysis. Returning to the pocket
change analogy, pennies are broken down into copper and zinc,
whereas nickels, dimes, and quarters into copper and nickel.
Analytes of copper, nickel, and zinc would be qualitatively
(what kind) and quantitatively (how much) reported, rather

Fatty acid oxidation disorders occur when an enzyme is
missing or significantly decreased in the metabolic pathway.
A summary of fatty acid disorders detected through MS/MS
during the neonatal period is provided in Table 1.18-20 They are
listed according to the length of the fatty acid chain as detected
by newborn screening using MS/MS. In a newborn's dried filter
paper blood spot, one of the components that MS/MS tests for is
acylcarnitines, fats that have been attached to a carnitine.27
Carnitine is an ammonium compound that has a key role in the
transport of fats in and out of the mitochondria, the cell's energy
factory.28 An acylcarnitine is identified by the size of the fat
molecule attached to it. These are categorized as short, medium,
and long-chain fatty acids and are abbreviated as a combination
of letters and numbers (Table 2).

Diagnosis of Fatty Acid Oxidation by MS/MS
As early as 1984, the diagnostic value of analysis of
acylcarnitines was demonstrated and eventually was used to
identify medium chain acyl-CoA dehydrogenase (MCAD)
deficiency using newborn dried blood spots when C8
(octanoylcarnitine) concentration and a ratio of C8/C10 are
greater than four to one.24,27,29,30 In 2005, a consensus
statement was issued to screen without further delay at least
for MCAD deficiency in all 50 states.31

Metabolic Effects of Impaired Fatty Acid
Metabolism
In FAODs, specific enzymes that are needed in the
conversion of fat to energy are either significantly decreased
or absent within the normal mitochondrial pathway (Fig 4).32,33

Fig 2. Simplified schematic of the components of a mass spectrometer. Reprinted from Banta-Wright SA,
Steiner RD. Tandem mass spectrometry in newborn screening: A primer for neonatal and perinatal nurses.
J Perinat Neonatal Nurs 2004;18(1):59-60 with permission from Lippincott Williams & Wilkins.

Fig 3. Simplified components of a tandem mass spectrometer. Reprinted from Banta-Wright SA, Steiner RD.
Tandem mass spectrometry in newborn screening: A primer for neonatal and perinatal nurses. J Perinat
Neonatal Nurs 2004;18(1):59-60 with permission from Lippincott Williams & Wilkins.
Usually, these pathways are mediated by coenzyme A (CoA),
leading to the formation of acetyl-CoA. When there is a block
within the pathway, an abnormal amount of a specific acetylCoA begins to accumulate in the blood and tissues of the body,
leading to both intoxication and energy deficiency (Fig 5). With
the accumulation of fatty acyl-CoA species, the secondary
metabolite produces intoxication, such as the accumulation of
ammonia. The shortage of acetyl-CoA impairs hepatic ketogensis and the synthesis of ATP by the oxidation phosphorylation pathway. This results in energy depletion, such as the
absence of ketones to extrahepatic tissues.

Specific Disorders of Fatty Acid Oxidation
Fatty acid oxidation disorders develop in the absence or
significant reduction of a specific enzyme needed in the
metabolic degradation of fatty acids. Three common deficiencies of FAOD are described in detail according to the length of
the acylcarnitine molecule.

Carnitine Palmitoyltransferase 1 Deficiency
Carnitine palmitoyltransferase I (CPT I) deficiency is a
disorder of long-chain fatty acid oxidation that is autosomal
recessive. The enzyme CPT I is located on the outer
membrane of the mitochondria and is vital in the transfer of
long-chain fatty acids into the mitochondria (Fig 6).33-35
Before long-chain fats can be catabolized, the long-chain fats
are changed to their CoA esters by long-chain acyl-CoA
synthetases located in the mitochondrial outer membrane.
Carnitine palmitoyltransferase I catalyzes the transfer of the
long-chain acyl-CoA esters to carnitine, which is transported
across the mitochondrial inner membrane by carnitine
acylcarnitine carrier. Once inside on the inner membrane,
carnitine palmitoyltransferase II (CPT II) then reverses the
CPT I reaction, reconverting the acyl-CoA in the mitochon-

drial matrix, which can then serve as a substrate for β-oxidation and releasing carnitine. In CPT I deficiency, longchain fatty acids are not transferred from acyl-CoA esters to
carnitine to acylcarnitines by CPT I.36 Thus, no acylcarnitines are made and do not enter the mitochondria for
subsequent β-oxidation. The defect leads to inadequate
formation of ketones bodies in response to fasting along
with inadequate gluconeogenesis and hypoglycemia. This is
characterized by metabolic decompensation occurring with
fasting or catabolic stress, such as a fever.35-37 The classic
clinical presentation may include lethargy, seizures, coma,
and hepatomegaly, and can be associated with potentially
fatal hypoketotic hypoglycemia.
The first description of CPT I deficiency was in 1980.38
Before MS/MS, less than 50 people worldwide had been
diagnosed with CPT I deficiency. In 2001, CPT deficiency was
identified in dried newborn blood spots using MS/MS.39
Analysis from MS/MS revealed a significantly elevated free
carnitine and increased free carnitine to the sum of palmitoylcarnitine and stearoylcarnitine (C0/C16 + C18). At the same
time, a specific CPT I polymorphism was identified within the
American and Canadian Hutterites of the Northern Plains.40
This led to the development of a pilot project for a DNA based
newborn screening program to better identify newborns at risk
within this population.41 Subsequently, a different CPT I
polymorphism has been identified within the Alaska Natives,
Inuit and First Nation tribes in Alaska and Canada from
newborn screening with MS/MS.42-44 The current treatment
recommendation is simply the avoidance of fasting and the
provision of caloric support during times of stress, such as
diarrhea or vomiting. Carnitine supplementation is not needed
because these infants have an abundance of free carnitine. The
natural history of CPT I within these three groups is unknown.
Further studies will be needed to determine how common the
specific polymorphisms are within each of the groups and to
determine the health consequences of the mutation in these
populations. Additional studies will also be needed to

Table 2. Fatty Acid Oxidation Disorders Associated with Abnormal Carnitine and Acylcarnitine
Analyte Levels from Tandem Mass Spectrometry During the Neonatal Period
Change
Analyte
C0

Name of Acylcarnitine
Carnitine (total)

↑

↓

X
X
X

C2
C4
C4-OH
C5
C5-DC
C6
C8
C8-OH
C10
C10-OH
C10:1
C10:2
C12
C14
C14:1
C14:2
C16

Acetyl
Butyryl
3-Hydroxybutrylcarnitine
Isovaleryl
Glutaryl
Hexanoyl
Octanoyl
Hydroxyoctanoylcarnitine
Decanoyl
Hydroxydecanolycarnitine
Decenoyl
Decadienoylcarnitine
Dodecanoyl
Tetradecanoyl
Tetradecenoyl
Tetradodecenoyl
Palmitoyl

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

C16-OH
C18

3-Hydroxypalmitoyl
Octadecanoyl

X
X

C18:1

Linoleoyl

X

C18:1-OH

3-Hydroxylinoleoyl

X

X

X
X

Fatty Acid Oxidation Disorder
to Consider
CPT I
CUD
CUD or Insufficiency
SCAD, MADD
MCHAD, SCHAD
GA II
GA II
GA II, MCAD
MCAD, MCAT
MCAT
MCAD
MCAT
MCAD
DE RED
GA II
VLCAD
VLCAD
VLCAD
CACT, CPT II, GA II, LCHAD, VLCAD
CPT I
LCHAD, TFP
CPT II, VLCAD
CPT I
CACT, CPT II, GA II, LCHAD, VLCAD
CPT I
LCHAD, TFP

Data from Sweetman L, Millington DS, Therrel BL et al: Naming and Counting Disorders (Conditions) Included in Newborn Screening Panels. Pediatrics.
2006;117:S308-S314. Millington DS: Tandem mass spectrometry in clinical diagnosis, in Blau N, Duran M, Blaskovics ME, Gibson KM (eds.): Physician's Guide to
the Laboratory Diagnosis of Metabolic Diseases. 2nd ed. Berlin, Germany, Springer, pp 57-85,2003; Northwest Regional Newborn Screening Program: MS/MS
Cutoffs, Follow up Tests. Portland, Oregon: 2005.
CACT = carnitine acylcarnitine translocase deficiency, CPT I = carnitine palmitoyltransferase I deficiency, CPT II = carnitine palmitoyltransferase II deficiency,
CUD = carnitine uptake defect/transporter deficiency, DE RED = 2,4-dienoyl-CoA reductase deficiency, GA II = glutaric acidemia II ( also known as MADD =
multiple acyl CoA dehydrogenase deficiency and Ethylmalonic-adipic aciduria), LCHAD = long-chain L-3-hydroxyacyl CoA dehydrogenase deficiency, MCAD =
medium chain acyl CoA dehydrogenase deficiency, MCAT = medium chain ketoacyl-CoA thiolase deficiency, MCHAD = medium chain L-3-hydroxyacyl CoA
dehydrogenase deficiency, SCAD = short-chain acyl CoA dehydrogenase deficiency, SCHAD = Short chain L-3-hydroxyacyl CoA dehydrogenase deficiency,
TFP = Trifunctional protein deficiency, VLCAD = Very long chain acyl CoA dehydrogenase deficiency.

determine whether all of the affected infants are being identified
via MS/MS analysis or if screening via DNA mutation analysis is
required for full ascertainment.

Medium Chain Acyl-CoA Dehydrogenase Deficiency
Medium chain acyl-CoA dehydrogenase deficiency is the
most common disorder of fatty acid oxidation.45 The incidence
of MCAD deficiency is estimated at 1/6000 to 1/25 000 white
births.46-49 This makes MCAD the most common inborn error of
metabolism disorder, even more common than PKU, a disorder
screened for in all American states and many countries. Medium
chain acyl-CoA dehydrogenase deficiency is an autosomal
recessive disorder that was first described in 1982.50 The gene

for MCAD is located on chromosome 1, and the nucleotide
sequence of its complementary DNA has been established.51 The
most common mutation in people of Northern European
descent is in the nucleotide 985 where A has been changed to G,
leading to a lysine to glutamic acid change in the residue 329 of
the protein.19,46-48 Between 75% and 80% of patients are
homozygous for this common mutation, whereas another 18%
are heterozygous for this mutation on one allele.19,47-49,51,52 No
other common mutation has been identified.46,53 There appears
to be no clear correlation between mutation type (the genetic
defect) and clinical phenotype (the physical characteristics).54
The enzyme MCAD is one of the mitochondrial acyl CoA
dehydrogenases that are needed to catalyze the initial steps in the
β -oxidation of fatty acids during hepatic ketogenesis (Fig. 6).
Medium chain acyl-CoA dehydrogenase involves fatty acyl-

Fig 4. Pathway of fatty acid metabolism. This schematic shows the transport of long-chain fatty acids and
carnitine across the plasma membrane to the production of acetyl-CoA. Medium and short-chain fatty acids
do not require an active transport mechanism to reach the mitochondrial matrix. Enzymes of the carnitine
cycle (CPT I, CACT, and CPT II) shuttle long-chain fatty acids across the mitochondrial membranes. The fatty
acid β -oxidation spiral includes an FAD-dependent acyl-CoA dehydrogenase step (1) followed by a 2,3
enoyl-coA hydratase reaction (2), the NAD-dependent 3-hydroxyacyl-CoA dehydrogenase step (3), and the
thiolase cleavage reaction (4). Oxidation of long-chain fatty acids, which are membrane bound enzymes, and
medium- and short-chain fatty acids, which are within the matrix, are shown separately. Reducing equivalents
(FADH 2 and NADH+H + ) are directed to the oxidation phosphorylation pathway (right). CACT indicates
carnitine acylcarnitine translocase; IMM, inner mitochondrial membrane; OMM, outer mitochondrial
membrane; TCA, tricarboxylic acid; TFP, trifunctional protein. Figure designed by J. Joshua, Jacobson (Mayo
High School Gifted and Talented Education Program, Rochester, MN.) Reprinted, with permission, from the
Annual Review of Physiology, Volume 64 © 2002 by Annual Reviews www.annualreviews.org”.
CoAs within an acid length of 6 to 12 carbons. The metabolic
block in MCAD deficiency results in the inability to oxidize fatty
acids to produce energy.55
The clinical presentation of MCAD deficiency during infancy
can range from a severe clinical course with metabolic acidosis
and hyperammonemia, hypoketotic hypoglycemia, hepatic fatty
infiltrates, cardiomyopathy, or sudden infant death to a mild
presentation with hypoglycemia to totally asymptomatic.56-63
The classic management of MCAD deficiency has been simply
the avoidance of fasting and the provision of caloric support
during times of stress, such as childhood illnesses.63 The
prognosis is excellent when the diagnosis is established and
frequent feedings are instituted to avoid prolonged fasting.58
Supplementation with carnitine is controversial. Oral carnitine
supplementation ranges from 50 to 100 mg/kg per day of
carnitine to correct the secondary carnitine deficiency and to
enhance the elimination of toxic metabolites.48 Initial studies

with oral carnitine supplementation reported an increase in the
conjugation and subsequent urinary excretion of acyl
groups.64,65 There was an increase in the availability of free
CoA and decreased acyl-CoA accumulation in the mitochondria. Other studies revealed findings that cast doubt on the
value of long-term treatment with carnitine in patients with
MCAD.66 The supplementation of carnitine inhibited glycine
conjugation, which is the major pathway for the disposal of C6
to C8 acylcarnitine analytes. No randomized double-blind
study has been done to answer the question if supplementation
with carnitine is needed in patients with MCAD.

Very Long-Chain Acyl-CoA Dehydrogenase
Deficiency
Very long-chain acyl CoA dehydrogenase (VLCAD) deficiency is the most common mitochondrial β -oxidation defect of

Fig 5. Impaired fatty acid metabolism of a generic
enzyme reaction. A is the substrate. B is the product.
C is a product of an alternative pathway. Adapted
from P. Rinaldo, Matern D: Disorders of fatty acid
transport and mitochondrial oxidation. Genet Med.
2 (2000) 338-344 with permission from Lippincott
Williams & Wilkins.
long-chain fatty acids. 67 However, the incidence is rare,
approximately 1:50 000 to 1:100 000 births.68 Originally
described in the early 1990s, VLCAD deficiency is an autosomal
recessive genetic disorder that results in the inability to oxidize
long-chain fatty acids to produce energy (Fig. 6) that is needed
by highly oxidative organs, such as the heart.69-71 Very longchain acyl CoA dehydrogenase is an enzyme within the
mitochondrial matrix and catalyses the first step in the β oxidation spiral of long-chain fatty acids.72,73 Very long-chain
acyl CoA dehydrogenase involves fatty acyl CoAs in the acid
length of 14 to 20 carbons length. This is not much larger than
the 12- to 18-carbon range of the mitochondrial matrix enzyme,
long-chain acyl CoA dehydrogenase (LCAD). As a result, several
patients originally identified as having LCAD deficiency in
reality had VLCAD deficiency.74 One case of VLCAD deficiency
reported was identified retrospectively to determine if the case
would have been identified by MS/MS on the newborn's original
newborn screening card.75 The acylcarnitine profile from the
newborn's original newborn screening card was analyzed 2
years after it was obtained. There was a significant accumulation
of long-chain acylcarnitines with a significant peak of
tetradecenoylcarnitine (C14:1), the identified marker of
VLCAD deficiency. Subsequently, through newborn screening
using MS/MS, eight asymptomatic infants were identified.67
Biochemical testing confirmed VLCAD in all cases.
The clinical presentation of VLCAD deficiency during
infancy can range from a severe clinical course with metabolic
acidosis, hypoketotic hypoglycemia, massive hepatic
fatty infiltrates, hypertrophic cardiomyopathy, or sudden
death to a mild presentation of hypoglycemia to totally
asymptomatic.68,73-80 Several studies have demonstrated a
clear genotype-phenotype relationship between the mutation
with clinical phenotype.68,81-83 Infants with severe clinical

presentations have mutations that result in no residual enzyme
activity, whereas infants with milder presentations have
mutations that result in residual enzyme activity. This is in
stark contrast to what has been observed in MCAD deficiency,
in which no correlation between genotype and phenotype can
be established.51,54,84,85
The management of VLCAD deficiency has included a
high-carbohydrate low long-chain fat diet with medium chain
triglyceride supplementation, the avoidance of fasting, and the
prompt intervention with parenteral glucose solutions when
fasting is unavoidable or due to stress as with vomiting or
fever.85,86 Dietary management with asymptomatic infants
varies from implementation of the classic diet to the
continuation of full breastfeeding with diet modification
after transition to solids with close monitoring of
complications. 68 In addition, carnitine supplement is
controversial.76,87 Recent research has revealed that low
carnitine concentrations in plasma associated with increased
production and accumulation of long-chain acylcarnitines do
not reflect carnitine homeostasis in tissues.67 Long-term
follow-up of infants with VLCAD is needed to determine
outcomes and to define the risk of future complications and
appropriate treatment options.

Implications for Clinical Care
Families need to be educated regarding the importance of
newborn screening and the specific disorders that are screened
for in the state where their infant is born. Not all states and
territories screen for FAOD using MS/MS. As of July 2007, 46
states use MS/MS for newborn screening.88 Within this group,
the FAOD screened for varies. In addition, results of the
newborn screen are usually not available at the time of discharge
from the normal newborn nursery. Parents should be
encouraged to ask their primary care provider about the results
at their first follow-up clinic visit. Early diagnosis improves
outcome. Most of the therapies are lifelong and requires
continual nutritional, medical, and laboratory monitoring. As
infants are surviving into childhood and adulthood, their longterm physical, mental, and emotional needs are becoming
increasingly important. As these children reach adulthood, their
reproductive abilities and the teratogenic effect that their disease
or its treatment can have on their children are unknown.

Summary
With MS/MS, the world of newborn screening has changed
from the “one test-one disorder” system to “one test-many
disorders.” Disorders of fatty acid oxidation can be rapidly
identified with a dried newborn blood spot on filter paper that is
used to detect many other inborn error of metabolism. MS/MS
allows the opportunity to identify many newborns with a FAOD
before a catastrophic insult, thus, decreasing morbidity and
mortality. In addition, MS/MS allows improved understanding
of the natural history of FAODs, such as CPT I, MCAD, and
VLCAD deficiencies. With appropriate support for biochemical

Fig 6. Simplified diagram of the fatty acid oxidation pathway with location of enzyme within the
mitochondria and identification of possible FAOD when enzyme reaction is impaired. MCAT deficiency
indicates medium chain ketoacyl-CoA thiolase deficiency; SCAD deficiency, short-chain acyl CoA
dehydrogenase deficiency; SCHAD deficiency, short-chain L-3-hydroxyacyl CoA dehydrogenase deficiency;
TFP deficiency, trifunctional protein deficiency.
genetics expertise, MS/MS used in newborn screening programs
can provide a positive impact on the health of infants with a
FAOD and their families.
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1. http://www.fodsupport.org/: Fatty oxidation disorders communication network.
2. http://www.simd.org/: Society for Inherited Metabolic Disorders (USA).

3. http://www.ssiem.org.uk/ssiemj.html: Society for the Study
of Inborn Errors of Metabolism (UK).
4. http://www.franken.de/lists/metab-l/: Inborn errors of metabolism list for professionals.
5. http://www.tylerforlife.com: Tyler for Life Foundation (newborn screening).
6. http://genes-r-us.uthscsa.edu: National Newborn Screening
and Genetics Resource Center.
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